Data from STELLAR Registration Trial of Tumor Treating Fields in Mesothelioma to be Presented at the IASLC 19th World Conference on Lung Cancer
Mesothelioma patients who received Tumor Treating Fields with pemetrexed and cisplatin or carboplatin experienced median overall survival of 18.2 months compared to 12.1 months in historical control with no increase in systemic toxicity Data will be highlighted in an oral presentation at world’s largest meeting dedicated to lung cancer and other thoracic malignancies ST. HELIER, …